Last reviewed · How we verify

Pseudomonas Aeruginosa Meningitis — Treatment Landscape & Competitive Intelligence

Pseudomonas Aeruginosa Meningitis (disease) competitive landscape: 3 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

3 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Pseudomonas Aeruginosa Meningitis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Arikayce Kit AMIKACIN Bristol-Myers Squibb Aminoglycoside Antibacterial 1981-01-01
Garamycin GENTAMICIN Merck & Co. Aminoglycoside Antibacterial Transient receptor potential cation channel subfamily V member 5 1970-01-01
Gentamicin Gentamicin Sulfate Merck & Co. gentamicin Dihydrofolate reductase 1970-01-01

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Merck & Co. · 2 drugs in Pseudomonas Aeruginosa Meningitis
  2. · 1 drug in Pseudomonas Aeruginosa Meningitis
  3. Bristol-Myers Squibb · 1 drug in Pseudomonas Aeruginosa Meningitis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Pseudomonas Aeruginosa Meningitis:

Cite this brief

Drug Landscape (2026). Pseudomonas Aeruginosa Meningitis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/pseudomonas-aeruginosa-meningitis. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing